Advanced

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

Heurling, Kerstin ; Ashton, Nicholas J. ; Leuzy, Antoine LU ; Zimmer, Eduardo R. ; Blennow, Kaj LU ; Zetterberg, Henrik LU ; Eriksson, Jonas ; Lubberink, Mark and Schöll, Michael LU (2019) In Molecular and Cellular Neuroscience 97. p.34-42
Abstract

Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarkers, Position emission tomography, SV2A, Synaptopathies
in
Molecular and Cellular Neuroscience
volume
97
pages
34 - 42
publisher
Elsevier
external identifiers
  • pmid:30796959
  • scopus:85062658024
ISSN
1044-7431
DOI
10.1016/j.mcn.2019.02.001
language
English
LU publication?
yes
id
a34c9611-6c2f-4500-8a43-168d29d23ccd
date added to LUP
2019-03-19 14:34:29
date last changed
2020-02-19 05:23:19
@article{a34c9611-6c2f-4500-8a43-168d29d23ccd,
  abstract     = {<p>Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.</p>},
  author       = {Heurling, Kerstin and Ashton, Nicholas J. and Leuzy, Antoine and Zimmer, Eduardo R. and Blennow, Kaj and Zetterberg, Henrik and Eriksson, Jonas and Lubberink, Mark and Schöll, Michael},
  issn         = {1044-7431},
  language     = {eng},
  pages        = {34--42},
  publisher    = {Elsevier},
  series       = {Molecular and Cellular Neuroscience},
  title        = {Synaptic vesicle protein 2A as a potential biomarker in synaptopathies},
  url          = {http://dx.doi.org/10.1016/j.mcn.2019.02.001},
  doi          = {10.1016/j.mcn.2019.02.001},
  volume       = {97},
  year         = {2019},
}